Polymyositis and dermatomyositis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(6 intermediate revisions by one other user not shown)
Line 4: Line 4:
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}  
==Overview==
==Overview==
The [[incidence]] of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The [[prevalence]] of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. The 5-year [[survival rate]] for polymyositis is 75% and for dermatomyositis is 63%. The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. Dermatomyositis has a [[Bimodal distribution|bimodal]] pattern, commonly affects both children and adults over 50 years old. Polymyositis commonly affects adults after second decades of their lives and it is rare among children. There is no racial predilection to polymyositis and dermatomyositis. The female to male ratio is approximately 2 to 1. Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide.<ref name="pmid9281381">{{cite journal |vauthors=Jacobson DL, Gange SJ, Rose NR, Graham NM |title=Epidemiology and estimated population burden of selected autoimmune diseases in the United States |journal=Clin. Immunol. Immunopathol. |volume=84 |issue=3 |pages=223–43 |date=September 1997 |pmid=9281381 |doi= |url=}}</ref>
*The [[incidence]] of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide.<ref name="pmid9281381">{{cite journal |vauthors=Jacobson DL, Gange SJ, Rose NR, Graham NM |title=Epidemiology and estimated population burden of selected autoimmune diseases in the United States |journal=Clin. Immunol. Immunopathol. |volume=84 |issue=3 |pages=223–43 |date=September 1997 |pmid=9281381 |doi= |url=}}</ref><ref name="KhanChristopher-Stine2011">{{cite journal|last1=Khan|first1=Sabiha|last2=Christopher-Stine|first2=Lisa|title=Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features|journal=Rheumatic Disease Clinics of North America|volume=37|issue=2|year=2011|pages=143–158|issn=0889857X|doi=10.1016/j.rdc.2011.01.001}}</ref>
*In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>
*In 2010, the [[incidence]] of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>
*In 1970, the age‐adjusted annual [[incidence]] of polymyositis was 5 cases per 100,000 individuals in USA hospital‐based retrospective study.<ref name="DalakasHohlfeld20033">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref>


===Prevalence===
===Prevalence===
*The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.<ref name="pmid9281381">{{cite journal |vauthors=Jacobson DL, Gange SJ, Rose NR, Graham NM |title=Epidemiology and estimated population burden of selected autoimmune diseases in the United States |journal=Clin. Immunol. Immunopathol. |volume=84 |issue=3 |pages=223–43 |date=September 1997 |pmid=9281381 |doi= |url=}}</ref>
*The [[prevalence]] of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.<ref name="SchiffenbauerFaghihi-Kashani2018">{{cite journal|last1=Schiffenbauer|first1=Adam|last2=Faghihi-Kashani|first2=Sara|last3=O’Hanlon|first3=Terrence P.|last4=Flegel|first4=Willy A.|last5=Adams|first5=Sharon D.|last6=Targoff|first6=Ira N.|last7=Oddis|first7=Chester V.|last8=Ytterberg|first8=Steven R.|last9=Aggarwal|first9=Rohit|last10=Christopher-Stine|first10=Lisa|last11=Shamim|first11=Ejaz A.|last12=Dellaripa|first12=Paul F.|last13=Danoff|first13=Sonye K.|last14=Mammen|first14=Andrew|last15=Miller|first15=Frederick W.|title=The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis|journal=Seminars in Arthritis and Rheumatism|year=2018|issn=00490172|doi=10.1016/j.semarthrit.2018.02.003}}</ref>
*In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.<ref name="BernatskyJoseph20082">{{cite journal|last1=Bernatsky|first1=S|last2=Joseph|first2=L|last3=Pineau|first3=C A|last4=Belisle|first4=P|last5=Boivin|first5=J F|last6=Banerjee|first6=D|last7=Clarke|first7=A E|title=Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences|journal=Annals of the Rheumatic Diseases|volume=68|issue=7|year=2008|pages=1192–1196|issn=0003-4967|doi=10.1136/ard.2008.093161}}</ref>
*In 2003, the [[prevalence]] of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.<ref name="BernatskyJoseph20082">{{cite journal|last1=Bernatsky|first1=S|last2=Joseph|first2=L|last3=Pineau|first3=C A|last4=Belisle|first4=P|last5=Boivin|first5=J F|last6=Banerjee|first6=D|last7=Clarke|first7=A E|title=Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences|journal=Annals of the Rheumatic Diseases|volume=68|issue=7|year=2008|pages=1192–1196|issn=0003-4967|doi=10.1136/ard.2008.093161}}</ref>
*In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>
*In 2010, the [[prevalence]] of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
* The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>
* The 5-year [[survival rate]] for polymyositis is 75% and for dermatomyositis is 63%.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>
*The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>
*The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref>


===Age===
===Age===
*Dermatomyositis commonly affects both children and adults.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref>
*Dermatomyositis has a [[Bimodal distribution|bimodal]] pattern, commonly affects both children and adults over 50 years old.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref><ref name="KhanChristopher-Stine2011">{{cite journal|last1=Khan|first1=Sabiha|last2=Christopher-Stine|first2=Lisa|title=Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features|journal=Rheumatic Disease Clinics of North America|volume=37|issue=2|year=2011|pages=143–158|issn=0889857X|doi=10.1016/j.rdc.2011.01.001}}</ref>
*Polymyositis commonly affects adults after second decades of their lives and it is rare among children.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref><ref name="DalakasHohlfeld20032">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref>
*Polymyositis commonly affects adults after second decades of their lives and it is rare among children.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref><ref name="DalakasHohlfeld20032">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref>


Line 29: Line 31:


===Region===
===Region===
*Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.<ref name="BernatskyJoseph2008">{{cite journal|last1=Bernatsky|first1=S|last2=Joseph|first2=L|last3=Pineau|first3=C A|last4=Belisle|first4=P|last5=Boivin|first5=J F|last6=Banerjee|first6=D|last7=Clarke|first7=A E|title=Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences|journal=Annals of the Rheumatic Diseases|volume=68|issue=7|year=2008|pages=1192–1196|issn=0003-4967|doi=10.1136/ard.2008.093161}}</ref>
*[[Prevalence]] of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.<ref name="BernatskyJoseph2008">{{cite journal|last1=Bernatsky|first1=S|last2=Joseph|first2=L|last3=Pineau|first3=C A|last4=Belisle|first4=P|last5=Boivin|first5=J F|last6=Banerjee|first6=D|last7=Clarke|first7=A E|title=Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences|journal=Annals of the Rheumatic Diseases|volume=68|issue=7|year=2008|pages=1192–1196|issn=0003-4967|doi=10.1136/ard.2008.093161}}</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


{{WH}}
[[Category:Medicine]]
{{WS}}
[[Category:Rheumatology]]
[[Category: (name of the system)]]
[[Category:Dermatology]]
[[Category:Up-To-Date]]

Latest revision as of 23:47, 29 July 2020

Polymyositis and dermatomyositis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyositis and dermatomyositis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyositis and dermatomyositis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyositis and dermatomyositis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyositis and dermatomyositis epidemiology and demographics

CDC on Polymyositis and dermatomyositis epidemiology and demographics

Polymyositis and dermatomyositis epidemiology and demographics in the news

Blogs on Polymyositis and dermatomyositis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Polymyositis and dermatomyositis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%. The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old. Polymyositis commonly affects adults after second decades of their lives and it is rare among children. There is no racial predilection to polymyositis and dermatomyositis. The female to male ratio is approximately 2 to 1. Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.

Epidemiology and Demographics

Incidence

  • The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide.[1][2]
  • In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually.[3]
  • In 1970, the age‐adjusted annual incidence of polymyositis was 5 cases per 100,000 individuals in USA hospital‐based retrospective study.[4]

Prevalence

  • The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.[5]
  • In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.[6]
  • In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.[3]

Case-fatality rate/Mortality rate

  •  The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%.[3]
  • The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years.[3]

Age

  • Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old.[7][2]
  • Polymyositis commonly affects adults after second decades of their lives and it is rare among children.[7][8]

Race

  • There is no racial predilection to polymyositis and dermatomyositis.

Gender

  • Females are more commonly affected by polymyositis and dermatomyositis than males. The female to male ratio is approximately 2 to 1.[7]

Region

  • Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.[9]

References

  1. ↑ Jacobson DL, Gange SJ, Rose NR, Graham NM (September 1997). "Epidemiology and estimated population burden of selected autoimmune diseases in the United States". Clin. Immunol. Immunopathol. 84 (3): 223–43. PMID 9281381.
  2. ↑ 2.0 2.1 Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
  3. ↑ 3.0 3.1 3.2 3.3 Airio, A.; Kautiainen, H.; Hakala, M. (2006). "Prognosis and mortality of polymyositis and dermatomyositis patients". Clinical Rheumatology. 25 (2): 234–239. doi:10.1007/s10067-005-1164-z. ISSN 0770-3198.
  4. ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
  5. ↑ Schiffenbauer, Adam; Faghihi-Kashani, Sara; O’Hanlon, Terrence P.; Flegel, Willy A.; Adams, Sharon D.; Targoff, Ira N.; Oddis, Chester V.; Ytterberg, Steven R.; Aggarwal, Rohit; Christopher-Stine, Lisa; Shamim, Ejaz A.; Dellaripa, Paul F.; Danoff, Sonye K.; Mammen, Andrew; Miller, Frederick W. (2018). "The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis". Seminars in Arthritis and Rheumatism. doi:10.1016/j.semarthrit.2018.02.003. ISSN 0049-0172.
  6. ↑ Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.
  7. ↑ 7.0 7.1 7.2 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
  8. ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
  9. ↑ Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.
Retrieved from "https://www.wikidoc.org/index.php?title=Polymyositis_and_dermatomyositis_epidemiology_and_demographics&oldid=1642377"